Characterization of the safety profile of TR-701 Free Acid (FA) in patients with major cutaneous abscess or cellulitis/erysipelas.
This is an open-label, multicenter study of oral TR-701 FA 200 mg once daily for 6 days for the treatment of major cutaneous abscess or cellulitis/erysipelas in patients 18 years of age or older. This study is designed to further characterize the safety profile and gather additional lesion measurement data of TR-701 FA in patients with major cutaneous abscess or cellulitis/erysipelas.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
200
1 tablet 200 mg once daily
Trius Investigator Site #118
Anaheim, California, United States
Trius Investigator Site #129
Buena Park, California, United States
Trius Investigator Site 103
Chula Vista, California, United States
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Safety will be assessed through summaries of the incidence of AEs and SAEs as well as through summaries of vital signs, physical examinations, ECG findings, and laboratory assessments (hematology, serum chemistry, and urinalysis).
Time frame: 24-31 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Trius Investigator Site 105
La Mesa, California, United States
Trius Investigator Site #106
Long Beach, California, United States
Trius Investigator Site 104
Oceanside, California, United States
Trius Investigator Site 101
Columbus, Georgia, United States
Trius Investigator Site 102
Savannah, Georgia, United States
Trius Investigator Site 128
Las Vegas, Nevada, United States
Trius Investigator Site 115
Somers Point, New Jersey, United States